Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

NCT01140373 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: engineered autologous T cells
DRUG: cyclophosphamide

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]